Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP
Andrew E. Hendifar, MD
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Jennifer Johnson, MD, PhD
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
June 17, 2026
04:30 PM - 05:15 PM CEST
June 24, 2026
06:00 PM - 06:45 PM CEST
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD
Alexander Spira, MD, PhD, FACP
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Chandrikha Chandrasekharan, MBBS
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Amy Comander, MD
Matching TNBC Treatment Intensity to Patient Needs
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.